Hinge Health (NYSE:HNGE) President Sells $2,905,650.00 in Stock

Hinge Health Inc. (NYSE:HNGE) President James Pursley sold 33,000 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $88.05, for a total transaction of $2,905,650.00. Following the completion of the transaction, the president directly owned 706,235 shares of the company’s stock, valued at $62,183,991.75. This trade represents a 4.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Pursley also recently made the following trade(s):

• On Monday, June 22nd, James Pursley sold 33,000 shares of Hinge Health stock. The stock was sold at an average price of $69.31, for a total value of $2,287,230.00.
• On Tuesday, May 26th, James Pursley sold 16,000 shares of Hinge Health stock. The shares were sold at an average price of $53.79, for a total value of $860,640.00.

Hinge Health Trading Up 0.7%

HNGE opened at $90.52 on Thursday. The firm has a market cap of $7.30 billion, a price-to-earnings ratio of 70.72 and a beta of 1.30. Hinge Health Inc. has a 12 month low of $30.08 and a 12 month high of $93.50. The stock has a fifty day moving average price of $82.72 and a 200-day moving average price of $59.66.

Hinge Health (NYSE:HNGE) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.31. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%.The company had revenue of $212.82 million for the quarter. During the same period in the previous year, the business earned $0.59 EPS. Hinge Health’s revenue for the quarter was up 53.0% compared to the same quarter last year. On average, equities research analysts forecast that Hinge Health Inc. will post 1.25 EPS for the current year.

Hedge Funds Weigh In On Hinge Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its position in shares of Hinge Health by 162.7% in the 4th quarter. BNP Paribas Financial Markets now owns 727,672 shares of the company’s stock valued at $33,800,000 after acquiring an additional 450,643 shares during the period. UBS Group AG lifted its position in Hinge Health by 168.8% during the 4th quarter. UBS Group AG now owns 356,701 shares of the company’s stock worth $16,569,000 after acquiring an additional 223,980 shares during the period. Royce & Associates LP purchased a new stake in Hinge Health during the 4th quarter valued at about $2,091,000. Alkeon Capital Management LLC increased its holdings in shares of Hinge Health by 110.4% in the fourth quarter. Alkeon Capital Management LLC now owns 791,104 shares of the company’s stock valued at $36,747,000 after purchasing an additional 415,093 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Hinge Health by 755.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company’s stock worth $1,271,000 after purchasing an additional 24,155 shares during the last quarter.

Analyst Upgrades and Downgrades

HNGE has been the topic of a number of analyst reports. Raymond James Financial lifted their price objective on shares of Hinge Health from $70.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Wall Street Zen cut shares of Hinge Health from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Wells Fargo & Company raised their target price on shares of Hinge Health from $90.00 to $103.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on shares of Hinge Health from $75.00 to $110.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Morgan Stanley upped their price target on Hinge Health from $72.00 to $108.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Hinge Health presently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.